Alpha Tau Medical Ltd. Ordinary Shares DRTS
i
Market datapartial · fetched 2026-11-04T07:29:58.301Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T23:11:12.335161994Z
FundamentalsAlpha Vantage · unavailable
Alpha Tau Medical Ltd. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 16.44 | 92.5% | 24.1% | 10.88 | 131.8% | 22.5% |
| 25Δ | 15.87 | 92.4% | 20.5% | 11.63 | 112.1% | 17.3% |
| 30Δ | 15.29 | 92.2% | 16.9% | 12.38 | 92.3% | 12.1% |
| 35Δ | 14.83 | 92.3% | 14.4% | 12.81 | 90.8% | 10.4% |
| 40Δ | 14.48 | 92.7% | 12.9% | 13.17 | 92.5% | 9.4% |
| 45Δ | 14.13 | 93.2% | 11.5% | 13.53 | 94.3% | 8.4% |
| 50Δ | 13.79 | 93.6% | 10.0% | 13.89 | 96.0% | 7.4% |
| 55Δ | 13.44 | 94.0% | 8.6% | 14.26 | 97.8% | 6.3% |
| 60Δ | 13.09 | 94.4% | 7.1% | 14.62 | 99.5% | 5.3% |
| 65Δ | 12.75 | 94.9% | 5.7% | 14.98 | 101.3% | 4.3% |
| 70Δ | 12.32 | 97.6% | 4.5% | 15.79 | 109.4% | 3.6% |
| 75Δ | 11.72 | 105.9% | 3.8% | 16.63 | 117.9% | 3.0% |
| 80Δ | 11.12 | 114.2% | 3.0% | 17.47 | 126.4% | 2.4% |
20Δ
- Pseudo strike
- 16.44
- IV
- 92.5%
- B/E move
- 24.1%
- Pseudo strike
- 10.88
- IV
- 131.8%
- B/E move
- 22.5%
25Δ
- Pseudo strike
- 15.87
- IV
- 92.4%
- B/E move
- 20.5%
- Pseudo strike
- 11.63
- IV
- 112.1%
- B/E move
- 17.3%
30Δ
- Pseudo strike
- 15.29
- IV
- 92.2%
- B/E move
- 16.9%
- Pseudo strike
- 12.38
- IV
- 92.3%
- B/E move
- 12.1%
35Δ
- Pseudo strike
- 14.83
- IV
- 92.3%
- B/E move
- 14.4%
- Pseudo strike
- 12.81
- IV
- 90.8%
- B/E move
- 10.4%
40Δ
- Pseudo strike
- 14.48
- IV
- 92.7%
- B/E move
- 12.9%
- Pseudo strike
- 13.17
- IV
- 92.5%
- B/E move
- 9.4%
45Δ
- Pseudo strike
- 14.13
- IV
- 93.2%
- B/E move
- 11.5%
- Pseudo strike
- 13.53
- IV
- 94.3%
- B/E move
- 8.4%
50Δ
- Pseudo strike
- 13.79
- IV
- 93.6%
- B/E move
- 10.0%
- Pseudo strike
- 13.89
- IV
- 96.0%
- B/E move
- 7.4%
55Δ
- Pseudo strike
- 13.44
- IV
- 94.0%
- B/E move
- 8.6%
- Pseudo strike
- 14.26
- IV
- 97.8%
- B/E move
- 6.3%
60Δ
- Pseudo strike
- 13.09
- IV
- 94.4%
- B/E move
- 7.1%
- Pseudo strike
- 14.62
- IV
- 99.5%
- B/E move
- 5.3%
65Δ
- Pseudo strike
- 12.75
- IV
- 94.9%
- B/E move
- 5.7%
- Pseudo strike
- 14.98
- IV
- 101.3%
- B/E move
- 4.3%
70Δ
- Pseudo strike
- 12.32
- IV
- 97.6%
- B/E move
- 4.5%
- Pseudo strike
- 15.79
- IV
- 109.4%
- B/E move
- 3.6%
75Δ
- Pseudo strike
- 11.72
- IV
- 105.9%
- B/E move
- 3.8%
- Pseudo strike
- 16.63
- IV
- 117.9%
- B/E move
- 3.0%
80Δ
- Pseudo strike
- 11.12
- IV
- 114.2%
- B/E move
- 3.0%
- Pseudo strike
- 17.47
- IV
- 126.4%
- B/E move
- 2.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 63.00% | |
| 67.53% | |
| 65.11% | |
| 71.14% | |
| 70.66% | |
| 74.47% | |
| 80.52% | |
| 79.78% | |
| 82.32% | |
| 83.36% |
Biotechnology
DRUG
Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies for central nervous system…
More →DSGN
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad,…
More →DTIL
Description unavailable
More →DYN
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The…
More →EDIT
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is…
More →ELDN
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral…
More →